Journals / Klinik Psikiyatri Dergisi / 2020 / Cilt: 23 - Sayı: 1

Evaluation of long acting, oral and combination antipsychotic treatments in patients with psychotic disorder

Psikotik bozukluk tanılı hastalarda uzun etkili, oral ve kombinasyon antipsikotik tedavilerinin değerlendirilmesi

Pages
72–82
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Discussion: In our study, it was found that combination therapy with LAA was more preferred in clinically severe cases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to evaluate the clinical progress, the drug side effects and the relationship between clinical variables and the clinical progress of patients with psychotic disorder who use oral antipsychotic (OA), long-acting antipsychotic (LAA) and combination of two forms (OA+LAA).
📊
Key Findings & Data:Method: The variables of 250 patients with schizophrenia and other psychotic disorders were analyzed retrospectively from the patient database.
💡
Conclusion & Impact:Discussion: In our study, it was found that combination therapy with LAA was more preferred in clinically severe cases.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to evaluate the clinical progress, the drug side effects and the relationship between clinical variables and the clinical progress of patients with psychotic disorder who use oral antipsychotic (OA), long-acting antipsychotic (LAA) and combination of two forms (OA+LAA). Method: The variables of 250 patients with schizophrenia and other psychotic disorders were analyzed retrospectively from the patient database. The Brief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Positive symptoms (SAPS), the Scale for the Assessment of Negative Symptoms (SANS), Global Assessment of Functioning (GAF) measurements, clinical variables related to the disease and adverse effects were recorded in the database. The analysis was performed between three groups according to antipsychotic use as OA, LAA (2-4 weeks), OA+LAA with parametric and non-parametric statistical methods. Results: In OA+LAA users, BPRS scores were higher than those using OA or LAA. In OA users, the SAPS and SANS scores were lower and GAF scores were higher than those using OA+LAA. In 4-week LAA users, BPRS scores were higher than those using OA and 2-week LAA. Those with OA had lower SANS, SAPS scores than those with 4- week LAA, and GAF scores were higher than those using LAA for 2 weeks and 4 weeks. Discussion: In our study, it was found that combination therapy with LAA was more preferred in clinically severe cases. The use of LAA may lead to the use of multiple and high-dose drugs, unlike the intended use. Evidence-based data are needed in treatment algorithms in cases with low treatment response, including the use of long-acting forms.

Özet

Amaç: Bu çalışmada oral antipsikotik (OA), uzun etkili antipsikotik (UEA) ve her iki formun kombinasyonu (OA+UEA) ile izlenen psikotik bozukluk tanılı hastalarda klinik gidişat, ilaç yan etkilerinin değerlendirilmesi ve klinisyenlerin ilaç form tercihleri ile klinik değişkenler arasındaki ilişkinin incelenmesi amaçlanmıştır. Yöntem: Şizofreni ve diğer psikotik bozukluk tanılarıyla izlenen 250 hastanın veri tabanından sosyodemografik özellikleri, kullanılan antipsikotikler ve Kısa Psikiyatrik Değerlendirme Ölçeği (BPRS), Pozitif Belirtileri Değerlendirme Ölçeği (SAPS), Negatif Belirtileri Değerlendirme Ölçeği (SANS), İşlevselliğin genel değerlendirilmesi (GAF) puanları, ilaç yan etkileri incelenerek, OA, UEA (2-4 hafta), OA+UEA kullanan üç grup arasında parametrik ve non-parametrik istatistiksel yöntemler ile analiz yapılmıştır. Bulgular: OA+UEA kullananlarda BPRS skorları OA veya UEA kullananlara göre daha yüksektir. OA kullananlarda OA+UEA kullananlara göre SAPS ve SANS skorlarının düşük, GAF skorları daha yüksektir. 4 haftalık UEA kullananlarda BPRS puanları OA ve 2 haftalık UEA kullananlardan yüksektir. OA kullananların SANS, SAPS puanları 4 haftalık UEA kullananlara göre daha düşük, GAF puanları ise 2 haftalık ve 4 haftalık UEA kullananlardan yüksektir. Sonuç: Çalışmamızda klinik açıdan şiddetli olgularda UEA ile kombinasyon tedavilerinin daha çok tercih edildiği saptanmıştır. UEA kullanımı amaçlanandan farklı olarak çoklu ve yüksek doz ilaç kullanımına yol açabilmektedir. Tedavi algoritmalarında tedavi yanıtı düşük olgularda, uzun etkili formların kullanımını içeren kanıta dayalı verilere ihtiyaç vardır.

🔖

Cite This Article

Şafak, Y., BULUT, S. D., KARADAĞ, H., ÖRSEL, S. (2020). Evaluation of long acting, oral and combination antipsychotic treatments in patients with psychotic disorder. Klinik Psikiyatri Dergisi, Cilt: 23 - Sayı: 1, 72–82. https://ajindex.com/articles/208849

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Lieberman JA, Stroup TS, Perkins DO. Essentials of schizophrenia. Washington DC: American Psychiatric Publishing, 2011
  2. Leucht S, Hierl S, Kissling W, Dold M, Davis JM. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 2012; 200:97-106
  3. López-Muñoz F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry 2005; 17:113-135
  4. Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Fleischhacker WW, Gaebel W, Gerlach J, Guelfi JD, Kissling W, Lapierre YD, Lindstrom E, Mendlewicz J, Racagni G, Carulla LS, Schooler NR: Guidelines for depot antipsychotic treatment in schizophrenia: European Neuropsychopharmacology Consensus Conference in Sienna, Italy Eur Neuropsychopharmacol 1998; 8:55-66
  5. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002; 63:892-909
  6. Patel MX, Taylor M, David AS. Antipsychotic long-acting injections: mind the gap. Br J Psychiatry 2009; 52:4-5
  7. Kreyenbuhl J, Slade EP, Medoff DR, Brown CH, Ehrenreich B, Afful J, Dixon LB. Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia. Schizophr Res 2011; 131:127-132
  8. Johnson DA. Historical perspective on antipsychotic long-acting injections. Br J Psychiatry Suppl 2009; 52:7-12
  9. Van Kammen DP, Hurford I, Marder SR. First generation antipsychotics, in Kaplan and Sadock’s Comprehensive textbook of psychiatry. Edited by Sadock BJ, and Sadock VA, Philadelphia, Lippincott Williams and Wilkins, 2009, 3105-3127
  10. Dencker S, Axelson R. Optimising the use of depot antipsychotics. CNS Drugs 1996; 6:367–381
  11. Saddock BJ, Saddock VA. Klinik Psikiyatri. Aydin H, Bozkurt A (Çeviri Ed.
  12. Baskı, Ankara: Güneş Kitabevi Ltd. Sti., 2005
  13. Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179:290-299
  14. Taylor D. Psychopharmacology and adverse effects of antipsychotic longacting injections: a review. Br J Psychiatry 2009; 52: 13-19
  15. Aykut DS, Arslan FC, Tiryaki A, Özkorumak E, Karakullukçu S. İkinci Kuşak Antipsikotik Kullanan Hastalarda İlaç Yan Etkileri ve Yaşam Kalitesi: Uzun Etkili Enjeksiyon ve A